 |
Amarin Reports Fourth Quarter and Year-End 2011 Financial Results and Provides Update on Operations
29 Feb 2012
|
82.7 KB |
|
| |
BEDMINSTER, N.J. and DUBLIN, Ireland, Feb. 29, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company focused on cardiovascular disease, today announced financial results for the quarter and year ended December 31, 2011 and provided an update on company operations.
Key Amarin accomplishments si...
|
|
Amarin to Report Fourth Quarter and Year-End 2011 Results and Host Conference Call on February 29, 2012
22 Feb 2012
|
14.1 KB |
|
| |
BEDMINSTER, N.J. and DUBLIN, Ireland, Feb. 22, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company focused on cardiovascular disease, announced today that it will host a conference call with members of Amarin senior management to discuss the company's fourth quarter and year-end 2011 financial resul...
|
|
Amarin to Present at the CITI 2012 Global Healthcare Conference
22 Feb 2012
|
59.1 KB |
|
| |
BEDMINSTER, N.J. and DUBLIN, Ireland, Feb. 22, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that Joseph S. Zakrzewski, Amarin's Chairman and Chief Executive Officer, is scheduled to present a general corporate update at the CITI 2012 Glo...
|
|
Amarin Corporation Appoints Dr. Steven Ketchum to Head Research and Development and Announces Inducement Grant Under NASDAQ Rule 5635(c)(4)
16 Feb 2012
|
16.8 KB |
|
| |
BEDMINSTER, N.J., and DUBLIN, Ireland, Feb. 16, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that Steven Ketchum, Ph.D., has been appointed President of Research and Development, Senior Vice President, effective February 16, 2012. Dr. Ke...
|
|
Amarin Announces FDA Advisory Committee Will Not Be Scheduled in Connection With New Drug Application for AMR101
13 Feb 2012
|
59.2 KB |
|
| |
BEDMINSTER, N.J. and DUBLIN, Ireland, Feb. 13, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company with a focus on cardiovascular disease, announced today that it was informed by the U.S. Food and Drug Administration (FDA) that no advisory committee meeting will be scheduled in connection with the F...
|
|
Amarin to Present at the Leerink Swann 2012 Global Healthcare Conference
7 Feb 2012
|
61.0 KB |
|
| |
BEDMINSTER, N.J. and DUBLIN, Ireland, Feb. 7, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company with a focus on cardiovascular disease today announced that John F. Thero, Amarin's President, is scheduled to present at the Leerink Swann 2012 Global Healthcare Conference on Thursday, February 16, 20...
|
|
Amarin Corporation plc Announces Pricing of $150 Million of Exchangeable Senior Notes Due 2032
4 Jan 2012
|
63.4 KB |
|
| |
BEDMINSTER, N.J. and DUBLIN, Ireland, Jan. 4, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN) announced today that its wholly owned subsidiary, Corsicanto Limited, a private limited company incorporated under the laws of Ireland (the "Issuer"), priced its previously announced offering of $150 million in aggregate principal amount of e...
|
|
Amarin Corporation plc Announces Offering of $150 Million of Exchangeable Senior Notes Due 2032
3 Jan 2012
|
62.2 KB |
|
| |
BEDMINSTER, N.J., and DUBLIN, Ireland, Jan. 3, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN) announced today that its wholly owned subsidiary, Corsicanto Limited, a private limited company incorporated under the laws of Ireland (the "Issuer"), has commenced an offering of $150 million in aggregate principal amount of exchangeable se...
|
|
Amarin Commences 2012 With Letter to Shareholders
3 Jan 2012
|
83.0 KB |
|
| |
BEDMINSTER, N.J., and DUBLIN, Ireland, Jan. 3, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company with a focus on cardiovascular disease, today issued its annual letter to shareholders. The text of this letter, written by Joseph S. Zakrzewski, Chairman and Chief Executive Officer, and the managemen...
|
|
Amarin Announces Appointment of Joseph T. Kennedy as General Counsel and Issuance of Inducement Grant Under NASDAQ Rule 5635(c)(4)
19 Dec 2011
|
64.5 KB |
|
| |
BEDMINSTER, N.J., and DUBLIN, Ireland, Dec. 19, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company with a focus on cardiovascular disease, today announced the appointment of Joseph T. Kennedy to the newly created position of Senior Vice President, General Counsel. Mr. Kennedy will report to Joseph ...
|
|
Amarin Announces the Addition of Industry Veteran Patrick O'Sullivan to Board
14 Dec 2011
|
62.4 KB |
|
| |
BEDMINSTER, N.J. and DUBLIN, Ireland, Dec. 14, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that Patrick "Paddy" O'Sullivan has joined the Board of Directors as an independent director effective December 13, 2011. Mr. O'Sullivan will als...
|
|
Amarin Announces Dosing of First Patient in Cardiovascular Outcomes Study REDUCE-IT
7 Dec 2011
|
18.4 KB |
|
| |
BEDMINSTER, N.J., and DUBLIN, Ireland, Dec. 7, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company with a focus on cardiovascular disease, today announced the dosing of the first patient in REDUCE-IT, the cardiovascular outcomes study utilizing AMR101.
REDUCE-IT (Reduction of Cardiovascular ...
|
|
Amarin Announces FDA Acceptance for Filing of AMR101 NDA
25 Nov 2011
|
61.9 KB |
|
| |
BEDMINSTER, N.J. and DUBLIN, Ireland, Nov. 25, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company focused on cardiovascular disease, today announced that its New Drug Application (NDA) for AMR101 has been accepted for filing by the U.S. Food and Drug Administration (FDA). The acceptance of the NDA ...
|
|
Amarin Announces Resignation of David Feigal from Board of Directors
25 Nov 2011
|
61.4 KB |
|
| |
BEDMINSTER, N.J., and DUBLIN, Ireland, Nov. 25, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company focused on cardiovascular disease, today announced that Dr. David Feigal has resigned as a member of the Company's Board of Directors. Dr. Feigal cited a crush of other commitments as the reason for h...
|
|
Amarin Added to NASDAQ Biotechnology Index
21 Nov 2011
|
61.6 KB |
|
| |
BEDMINSTER, N.J., and DUBLIN, Ireland, Nov. 21, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company focused on cardiovascular disease, today announced that it has been selected for addition to the NASDAQ Biotechnology Index ® (Nasdaq:NBI), which will become effective at the open of U.S. markets...
|
|
Amarin's Phase 3 ANCHOR Study Results Presented at American Heart Association's Scientific Sessions 2011
16 Nov 2011
|
66.0 KB |
|
| |
BEDMINSTER, N.J., and DUBLIN, Ireland, Nov. 16, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company with a focus on cardiovascular disease, announced today the first presentation in a scientific session of data from Amarin's Phase 3 clinical trial, the ANCHOR study, in which patients with high trigl...
|
|
Amarin's Phase 3 MARINE Study Results Presented at American Heart Association's Scientific Sessions 2011
15 Nov 2011
|
65.8 KB |
|
| |
BEDMINSTER, N.J. and DUBLIN, Ireland, Nov. 15, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company with a focus on cardiovascular disease, today announced the presentation of data from Amarin's Phase 3 clinical trial, the MARINE study, in which patients with very high trigylcerides (≥500 mg/dl...
|
|
Amarin's Phase 3 MARINE and ANCHOR Study Data to be Presented at American Heart Association's Scientific Sessions 2011
14 Nov 2011
|
62.1 KB |
|
| |
BEDMINSTER, N.J. and DUBLIN, Ireland, Nov. 14, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company with a focus on cardiovascular disease, announced that data from each of its two pivotal Phase 3 studies, the ANCHOR trial and the MARINE trial, will be presented at the American Heart Association's Sc...
|
|
Amarin to Present at Two Upcoming Investor Conferences
10 Nov 2011
|
12.2 KB |
|
| |
BEDMINSTER, N.J., and DUBLIN, Ireland, Nov. 10, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company focused on cardiovascular disease today announced that it is scheduled to participate in two upcoming investor conferences: the Lazard Capital Markets 8th Annual Healthcare Conference on Tuesday, ...
|
|
Amarin Reports Third Quarter 2011 Results
7 Nov 2011
|
30.7 KB |
|
| |
BEDMINSTER, N.J., and DUBLIN, Ireland, Nov. 7, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company focused on cardiovascular disease, today reported financial and operating results for the quarter ended September 30, 2011 (Q3 2011). Highlights since the Company's last quarterly report included:
...
|
|
|
Delicious
Digg
Facebook
LinkedIn
Twitter